Silence Therapeutics PLC's (LON:SLN) chairman Iain Ross and CFO Rob Quinn speak to Proactive London's Andrew Scott after announcing its intention to list on the American growth market, Nasdaq.
Ross says in the US, RNAi is very hot at the moment and if you look at their competitor companies they're valued at a 'great deal more' than Silence.
''While we might not quite be at the same stage as they are in terms of development and number of deals we feel the company will be revalued in time''.
